Related Experiment Video

Updated: Mar 24, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.6K

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Xiaoman Li1, Changjing Wu1, Nianci Chen2

  • 1Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China.

Oncotarget
|March 12, 2016
PubMed

Insights

Glioblastoma multiform (GBM) treatments are limited. Targeting the epidermal growth factor receptor (EGFR) and PI3K/Akt/mTOR pathway shows promise for new GBM therapies, with ongoing clinical trials evaluating these inhibitors.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Glioblastoma multiform (GBM) is the most aggressive primary brain tumor.
  • Effective treatment options for GBM remain limited.
  • GBM often exhibits epidermal growth factor receptor (EGFR) overexpression or mutation, activating downstream signaling pathways.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway in GBM.
  • To provide an updated overview of clinical trials involving EGFR and PI3K/Akt/mTOR inhibitors for GBM treatment.

Main Methods:

  • Review of scientific literature on GBM pathogenesis and signaling pathways.
  • Analysis of clinical trial data for EGFR and PI3K/Akt/mTOR inhibitors in GBM.
  • Exploration of the rationale for targeting the PI3K/Akt/mTOR pathway.

Main Results:

  • The PI3K/Akt/mTOR pathway is frequently activated in GBM due to EGFR alterations.
  • Inhibition of this pathway represents a promising therapeutic strategy.
  • Several EGFR and PI3K/Akt/mTOR inhibitors are currently under investigation in clinical trials for GBM.

Conclusions:

  • Targeting the EGFR and PI3K/Akt/mTOR pathway is a rational therapeutic approach for GBM.
  • Ongoing clinical trials will determine the efficacy and safety of these targeted therapies.
  • Further research is needed to optimize treatment strategies for GBM patients.
Keywords:
EGFRPI3K/Akt/mTOR pathwayglioblastomatargeted therapy

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K